RAF265 – 50 mg

Brand:
Cayman
CAS:
927880-90-8
Storage:
-20
UN-No:
Non-Hazardous - /

RAF265 is a dual inhibitor of mutant B-RafV600E and vascular endothelial growth factor receptor 2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays).{27852} It can also inhibit wild-type B-Raf, platelet-derived growth factor receptor, colony-stimulating factor 1R, RET, c-KIT, SRC, and STE20 with IC50 values ranging from 20-100 nM.{27957} RAF265 can inhibit proliferation of melanoma and colorectal cancer cell lines with active BRAF mutations as well as suppress tumor growth in melanoma xenograft models bearing B-RafV600E mutations.{27957}  

 

Out of stock

SKU: - Category:

Description

A dual inhibitor of mutant B-RafV600E and VEGFR2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays) that also inhibits wild-type B-Raf, PDGFR, CSF1R, RET, c-KIT, SRC, and STE20 (IC50s = 20-100 nM)


Formal name: 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine

Synonyms:  CHIR265

Molecular weight: 518.4

CAS: 927880-90-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|RAS/RAF/MEK/ERK/MAPK||Product Type|Biochemicals|Kinase Inhibitors|SRC Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|ERK/MAPK Signaling||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling